SOLID TUMORS

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to deliver chemotherapy directly to cancer cells. The trial has two parts: P…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This early-stage trial tests a new drug called runimotamab, alone or with trastuzumab, in 123 people with advanced HER2-positive cancers. The main goal is to check safety and how the drug moves through the body. It is for patients whose cancer has spread or cannot be removed by s…

This early-stage study tests a new drug called JSI-1187, either alone or combined with dabrafenib, in people with advanced solid tumors that have certain genetic changes (MAPK pathway mutations). The main goal is to check safety and tolerability, with a secondary look at whether …

This study tests the safety and effectiveness of pembrolizumab, an immunotherapy drug, in 17 adults with MSI-H solid tumors who still have cancer DNA in their blood after surgery. Participants receive the drug every 3 weeks for up to 12 months. The main goal is to see if the drug…

This early-phase trial tests a new type of cell therapy for children and young adults with solid tumors that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are trained in the lab to recognize and attack multiple cancer…

This early-phase study tests a new drug called BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody), in adults with advanced solid tumors that have not responded to other treatments. The drug is injected directly into the tumor or infused into a vein. The main go…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already taking it in a previous Roche study and still benefiting. About 154 participants will receive pertuzumab every 3 weeks, alone or with other treatments, until th…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This early-stage trial is testing a new treatment called GK01 cell injection, given together with a PD-1 monoclonal antibody (a type of immunotherapy), for people with advanced solid tumors that have spread or come back. The study includes about 15 adults aged 18 to 70 with cance…

This study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…

This trial tests a new antibody drug called acasunlimab (GEN1046) in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, to find safe doses, and second, to see how well the drug works alone or combined with other cance…

This early-phase study tests a flavored, drinkable version of the chemotherapy drug irinotecan (VAL-413) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest dose and see how the…

This study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a toxin directly to cancer cells. About 250 adults will receive the drug alone or …

This early-phase study tests a combination of two targeted drugs, palbociclib and gedatolisib, in people with advanced lung, pancreatic, head & neck, or other solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and look for e…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…

This early-phase trial is testing a new experimental drug called BI-1910, given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors (including lung and liver cancers) that have not responded to standard treatments. The main goals are to see if the …

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This early-stage study tests an experimental pill, ATV-1601, in adults with advanced solid tumors or certain breast cancers that have a specific AKT1 gene change. The main goals are to find a safe dose and check how the drug moves through the body. About 134 participants will tak…

This early-stage study tests a new drug, GS-9911, alone or with an existing immunotherapy, in 45 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check safety and find the best dose. This is a first step to see if the drug might h…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This early-phase study tests an experimental drug called M9140 in 12 Chinese patients with advanced colorectal cancer that has not responded to standard treatments. The drug works like a guided missile, delivering chemotherapy directly to cancer cells that carry a specific marker…

This study tests whether combining two drugs, olaparib and pembrolizumab, can shrink or control advanced solid tumors that have certain DNA repair problems. About 300 adults whose cancer has not responded to standard treatments will receive the drug combination. The goal is to se…

This study was designed to test a new cell therapy called B7H3 CAR-T for people with advanced solid tumors that have a specific marker (B7H3). The goal was to see if the treatment is safe and shrinks tumors. However, the study was withdrawn before enrolling any participants, so n…

This early-phase study tests whether infusions of white blood cells (mainly granulocytes) from healthy, unrelated donors can help shrink solid tumors in 29 people with advanced cancer who have no other treatment options. Participants receive daily infusions from different donors …

This study offers continued treatment with avelumab, an immunotherapy drug, to people with advanced cancers (like lung, ovarian, or bladder cancer) who are already benefiting from it in earlier Pfizer studies. The goal is to keep providing the drug and monitor safety and survival…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This early-stage study tests an experimental drug called INCB186748 in people with advanced or spreading solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and find the right dose. About 30 adults whose cancer has not …

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This study tests an experimental drug called entrectinib in children and teens with advanced solid tumors or brain tumors that have come back or not responded to other treatments. The goal is to find the best dose and see if the drug shrinks tumors, especially in those with speci…

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests whether dexamethasone, a steroid, can improve fatigue, pain, nausea, and other symptoms in people with advanced solid tumors. Participants take the drug or a placebo by mouth twice daily for 14 days. The goal is to see if symptoms get better, which could improve …

This study tested whether panax ginseng can reduce fatigue and improve mood in people with advanced cancer. 165 participants rated their fatigue levels before and after taking ginseng or a placebo for 29 days. The goal was to see if ginseng leads to greater improvement in fatigue…

This Phase I study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib. 64 adults with advanced solid tumors who have not responded to standard treatments will take cediranib alone and then with rifampicin. The goal is …

This study collects blood samples from people already in other NIH clinical trials who are having or are expected to have serious side effects from their drugs. The goal is to measure drug levels in the blood to better understand why side effects happen. Up to 100 participants ag…

This study collects leftover tissue and blood samples from 1,200 adults with known or suspected cancer during their standard surgeries or biopsies. Researchers will compare cancerous and normal tissues to find differences that could lead to new treatments. No extra procedures are…

This study looks at how safe and doable different amounts of aerobic exercise are for people about to have surgery for solid tumors like breast, endometrial, or prostate cancer. About 60 participants will exercise at home while using apps and devices to track their activity. The …

This study aims to understand why some solid tumors stop responding to targeted therapies by analyzing their genetic profiles. Researchers will collect blood, saliva, and tumor samples from 2500 people with various cancers, including colorectal, breast, lung, and rare tumors. Som…

This study follows up to 500 children who received gene therapy for cancer through the National Cancer Institute. Researchers will monitor them for 15 years to detect any delayed side effects from the treatment. Participants will have regular check-ups and blood tests to track th…